Guidelines for the Management of Chronic Kidney Disease

Overview

Journal CMAJ

Date 2008 Nov 19

PMID 19015566

Citations 143

Authors

Adeera Levin

Brenda Hemmelgarn

Bruce Culleton

Sheldon Tobe

Philip McFarlane

Marcel Ruzicka

Kevin Burns

Braden Manns

Colin White

Francoise Madore

Louise Moist

Scott Klarenbach

Brendan Barrett

Robert Foley

Kailash Jindal

Peter Senior

Neesh Pannu

Sabin Shurraw

Ayub Akbari

Adam Cohn

Martina Reslerova

Vinay Deved

David Mendelssohn

Gihad Nesrallah

Joanne Kappel

Marcello Tonelli

Affiliations

Soon will be listed here.

Citing Articles

Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study.

Rao B, Wang D, Yang M, Zhao C, Cheng M, Li S BMC Infect Dis. 2025; 25(1):275.

PMID: 40001043 PMC: 11863899. DOI: 10.1186/s12879-025-10643-w.

Global availability of medications and health technologies for kidney care: A multinational study from the ISN-GKHA.

Kelly D, Jones E, Barday Z, Arruebo S, Caskey F, Damster S PLOS Glob Public Health. 2025; 5(2):e0004268.

PMID: 39928669 PMC: 11809785. DOI: 10.1371/journal.pgph.0004268.

Assessing the quality of CKD care using process quality indicators: A scoping review.

Zhou N, Chen C, Liu Y, Yu Z, Bello A, Chen Y PLoS One. 2024; 19(12):e0309973.

PMID: 39656690 PMC: 11630614. DOI: 10.1371/journal.pone.0309973.

Attitudes towards digital health technology for the care of people with chronic kidney disease: A technology acceptance model exploration.

Kaklamanou D, Nguyen L, Al-Abbadey M, Sangala N, Lewis R PLOS Digit Health. 2024; 3(10):e0000614.

PMID: 39383191 PMC: 11463739. DOI: 10.1371/journal.pdig.0000614.

Magnitude of multiple drug use and determinants of vulnerability among chronic kidney disease inpatients in Ethiopia: a multi-center study.

Zeleke T, Abebe R, Wondm S, Tegegne B BMC Nephrol. 2024; 25(1):332.

PMID: 39375593 PMC: 11460044. DOI: 10.1186/s12882-024-03773-x.

References

Block G, Klassen P, Lazarus J, Ofsthun N, Lowrie E, Chertow G . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15(8):2208-18. DOI: 10.1097/01.ASN.0000133041.27682.A2. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

Lewis E, Hunsicker L, Clarke W, Berl T, Pohl M, Lewis J . Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001; 345(12):851-60. DOI: 10.1056/NEJMoa011303. View

. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):854-65. View

Cheng A . Canadian Diabetes Association 2013 clinical practice guidelines for the prevention and management of diabetes in Canada. Introduction. Can J Diabetes. 2013; 37 Suppl 1:S1-3. DOI: 10.1016/j.jcjd.2013.01.009. View

. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis. 2006; 47(5 Suppl 3):S11-145. DOI: 10.1053/j.ajkd.2006.03.010. View

KLAHR S, Levey A, Beck G, Caggiula A, Hunsicker L, Kusek J . The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994; 330(13):877-84. DOI: 10.1056/NEJM199403313301301. View

. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1):S1-266. View

Kestenbaum B, Sampson J, Rudser K, Patterson D, Seliger S, Young B . Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol. 2004; 16(2):520-8. DOI: 10.1681/ASN.2004070602. View

10.

Gerstein H, Mann J, Yi Q, Zinman B, Dinneen S, Hoogwerf B . Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001; 286(4):421-6. DOI: 10.1001/jama.286.4.421. View

11.

Lachin J, Genuth S, Cleary P, Davis M, Nathan D . Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000; 342(6):381-9. PMC: 2630213. DOI: 10.1056/NEJM200002103420603. View

12.

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

13.

Martinez I, Saracho R, Montenegro J, Llach F . The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis. 1997; 29(4):496-502. DOI: 10.1016/s0272-6386(97)90330-9. View

14.

Meier-Kriesche H, Kaplan B . Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation. 2002; 74(10):1377-81. DOI: 10.1097/00007890-200211270-00005. View

15.

Culleton B, Walsh M, Klarenbach S, Mortis G, Scott-Douglas N, Quinn R . Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA. 2007; 298(11):1291-9. DOI: 10.1001/jama.298.11.1291. View

16.

Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M . Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999; 354(9176):359-64. DOI: 10.1016/S0140-6736(98)10363-X. View

17.

Wanner C, Krane V, Marz W, Olschewski M, Mann J, Ruf G . Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353(3):238-48. DOI: 10.1056/NEJMoa043545. View

18.

Nathan D, Cleary P, Backlund J, Genuth S, Lachin J, Orchard T . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25):2643-53. PMC: 2637991. DOI: 10.1056/NEJMoa052187. View

19.

Coresh J, Astor B, Greene T, Eknoyan G, Levey A . Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2002; 41(1):1-12. DOI: 10.1053/ajkd.2003.50007. View

20.

Donnelly L, Doney A, Hattersley A, Morris A, Pearson E . The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes. Diabet Med. 2006; 23(2):128-33. DOI: 10.1111/j.1464-5491.2005.01755.x. View